Literature DB >> 19820720

Doxorubicin-induced vasomotion and [Ca(2+)](i) elevation in vascular smooth muscle cells from C57BL/6 mice.

Bing Shen1, Chun-ling Ye, Kai-he Ye, Lan Zhuang, Jia-hua Jiang.   

Abstract

AIM: To explore the action of doxorubicin on vascular smooth muscle cells.
METHODS: Isometric tension of denuded or intact thoracic aortic vessels was recorded and [Ca(2+)](i) in isolated aortic smooth muscle cells was measured by using Fluo-3.
RESULTS: Doxorubicin induced phasic and tonic contractions in denuded vessels and increased levels of [Ca(2+)](i) in single muscle cells. Treatment with 10 micromol/L ryanodine had no effect on basal tension, but it did abolish doxorubicin-induced phasic contraction. Treatment with 10 mmol/L caffeine induced a transient phasic contraction only, and the effect was not significantly altered by ryanodine, the omission of extracellular Ca(2+) or both. Phenylephrine induced rhythmic contraction (RC) in intact vessels. Treatment with 100 micromol/L doxorubicin enhanced RC amplitude, but 1 mmol/L doxorubicin abolished RC, with an increase in maximal tension. Caffeine at 100 micromol/L increased the frequency of the RC only. In the presence of 100 micromol/L caffeine, however, 100 micromol/L doxorubicin abolished the RC and decreased its maximal tension. Treatment with 10 micromol/L ryanodine abolished the RC, with an increase in the maximal tension. In Ca(2+)-free solution, doxorubicin induced a transient [Ca(2+)](i) increase that could be abolished by ryanodine pretreatment in single muscle cells. The doxorubicin-induced increase in [Ca(2+)](i) was suppressed by nifedipine and potentiated by ryanodine and charybdotoxin.
CONCLUSION: Doxorubicin not only releases Ca(2+) from the sarcoplasmic reticulum but also promotes the entry of extracellular Ca(2+) into vascular smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19820720      PMCID: PMC4003006          DOI: 10.1038/aps.2009.145

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  28 in total

1.  Fetal rabbit pulmonary artery smooth muscle cell response to ryanodine is developmentally regulated.

Authors:  V A Porter; H L Reeve; D N Cornfield
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-10       Impact factor: 5.464

2.  Ca(2+) movement from leaky sarcoplasmic reticulum during contraction of rat arterial smooth muscles.

Authors:  M Asano; Y Nomura
Journal:  Eur J Pharmacol       Date:  2000-09-22       Impact factor: 4.432

3.  Adriamycin causes dual inotropic effects through complex modulation of myocardial Ca2+ handling.

Authors:  T Matsushita; M Okamato; J Toyama; I Kodama; S Ito; T Fukutomi; S Suzuki; M Itoh
Journal:  Jpn Circ J       Date:  2000-01

4.  Smooth muscle tissues express a major dominant negative splice variant of the type 3 Ca2+ release channel (ryanodine receptor).

Authors:  Dawei Jiang; Bailong Xiao; Xiaoli Li; S R Wayne Chen
Journal:  J Biol Chem       Date:  2002-12-05       Impact factor: 5.157

5.  Ryanodine sensitizes the Ca(2+) release channel (ryanodine receptor) to Ca(2+) activation.

Authors:  H Masumiya; P Li; L Zhang; S R Chen
Journal:  J Biol Chem       Date:  2001-08-15       Impact factor: 5.157

6.  Enhanced phenylephrine-induced rhythmic activity in the atherosclerotic mouse aorta via an increase in opening of KCa channels: relation to Kv channels and nitric oxide.

Authors:  J Jiang; P Thorén; G Caligiuri; G K Hansson; J Pernow
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

7.  Mechanism underlying enhanced endothelium-dependent vasodilatation in thoracic aorta of early stage streptozotocin-induced diabetic mice.

Authors:  Bing Shen; Chun-Ling Ye; Kai-He Ye; Jian-Jun Liu
Journal:  Acta Pharmacol Sin       Date:  2003-05       Impact factor: 6.150

8.  Effect of low-dose doxorubicin on calcium content and norepinephrine response in rat aorta.

Authors:  H F Dalske; K Hardy
Journal:  Eur J Cancer Clin Oncol       Date:  1988-06

9.  Doxorubicin directly binds to the cardiac-type ryanodine receptor.

Authors:  Kazuhiko Saeki; Ichiro Obi; Noriko Ogiku; Munekazu Shigekawa; Toshiaki Imagawa; Takeshi Matsumoto
Journal:  Life Sci       Date:  2002-04-05       Impact factor: 5.037

10.  Regulation of calcium sparks and spontaneous transient outward currents by RyR3 in arterial vascular smooth muscle cells.

Authors:  M Löhn; W Jessner; M Fürstenau; M Wellner; V Sorrentino; H Haller; F C Luft; M Gollasch
Journal:  Circ Res       Date:  2001-11-23       Impact factor: 17.367

View more
  4 in total

1.  GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.

Authors:  Minsuk Kim; Mathew J Platt; Tadao Shibasaki; Susan E Quaggin; Peter H Backx; Susumu Seino; Jeremy A Simpson; Daniel J Drucker
Journal:  Nat Med       Date:  2013-03-31       Impact factor: 53.440

2.  Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow.

Authors:  Amanda J Stolarz; Mustafa Sarimollaoglu; John C Marecki; Terry W Fletcher; Ekaterina I Galanzha; Sung W Rhee; Vladimir P Zharov; V Suzanne Klimberg; Nancy J Rusch
Journal:  J Pharmacol Exp Ther       Date:  2019-08-22       Impact factor: 4.030

3.  Doxorubicin Impairs Smooth Muscle Cell Contraction: Novel Insights in Vascular Toxicity.

Authors:  Matthias Bosman; Dustin N Krüger; Kasper Favere; Callan D Wesley; Cédric H G Neutel; Birgit Van Asbroeck; Owen R Diebels; Bart Faes; Timen J Schenk; Wim Martinet; Guido R Y De Meyer; Emeline M Van Craenenbroeck; Pieter-Jan D F Guns
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

4.  Protective Effects of Allicin on Acute Myocardial Infarction in Rats via Hydrogen Sulfide-mediated Regulation of Coronary Arterial Vasomotor Function and Myocardial Calcium Transport.

Authors:  Tianwei Cui; Weiyu Liu; Chenghao Yu; Jianxun Ren; Yikui Li; Xiaolu Shi; Qiuyan Li; Jinyan Zhang
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.